This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

This study has been completed.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01165268
First received: July 16, 2010
Last updated: November 16, 2016
Last verified: November 2016
  Purpose
It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.

Condition Intervention Phase
Type 2 Diabetes Mellitus Drug: Dapagliflozin Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin [ Time Frame: Before 7 days of oral administration of 10 mg of dapagliflozin ]
  • The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin [ Time Frame: After 7 days of oral administration of 10 mg of dapagliflozin ]

Secondary Outcome Measures:
  • Splay of the glucose titration curve [ Time Frame: Before 7 days of oral administration of 10 mg of dapagliflozin ]
  • Splay of the glucose titration curve [ Time Frame: After 7 days of oral administration of 10 mg of dapagliflozin ]
  • Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin [ Time Frame: Study Day 7 ]
  • Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin [ Time Frame: Study Day 8 ]

Enrollment: 24
Study Start Date: August 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Dapagliflozin (T2DM) Drug: Dapagliflozin
Tablets, Oral, 10 mg, Once daily, 7 days
Active Comparator: Dapagliflozin (Healthy Subjects) Drug: Dapagliflozin
Tablets, Oral, 10 mg, Once daily, 7 days

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria for T2DM

  • Diagnosis of T2DM
  • Must be on one of the following therapies: diet therapy alone, diet plus a sulfonylurea, diet plus metformin, or diet plus sulfonylurea plus metformin
  • Subjects taking metformin, and/or sulfonylurea must be on a stable dose for at least 2 months prior to study drug administration
  • Must have a fasting plasma glucose concentration ≤ 200 mg/dl, and HbA1C ≤ 10%

Inclusion criteria for healthy subjects:

  • Healthy subjects (as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations)

Inclusion criteria for all subjects:

  • Subjects with (eGFR ≥ 60 and ≤ 160 mL/min/1.73m² and urinary albumin excretion < 300 mg/g creatinine)
  • Body Mass Index (BMI) of 18 to 38 kg/m²
  • Men and women, ages 18 to 65 years, inclusive

Exclusion criteria for all subjects:

  • Subjects with Type 1 Diabetes or uncontrolled Type 2 Diabetes Mellitus
  • Subjects with T2DM with fasting plasma glucose > 200 mg/dL, healthy subjects with fasting plasma glucose > 105 mg/dL
  • Subjects with T2DM with HbA1C > 10.0%, healthy subjects with HbA1C > 6.8%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01165268

Locations
United States, California
Profil Institute For Clinical Research, Inc.
Chula Vista, California, United States, 91911
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01165268     History of Changes
Other Study ID Numbers: MB102-066
Study First Received: July 16, 2010
Last Updated: November 16, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on June 23, 2017